TY - JOUR
T1 - Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old
T2 - a retrospective analysis
AU - Al Saleh, Abdullah S.
AU - Visram, Alissa
AU - Parmar, Harsh
AU - Muchtar, Eli
AU - Buadi, Francis K.
AU - Dispenzieri, Angela
AU - Warsame, Rahma
AU - Lacy, Martha Q.
AU - Dingli, David
AU - Leung, Nelson
AU - Go, Ronald S.
AU - Gonsalves, Wilson I.
AU - Kourelis, Taxiarchis V.
AU - Hayman, Suzanne R.
AU - Kapoor, Prashant
AU - Gertz, Morie A.
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
AU - Kumar, Shaji K.
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - This is a retrospective study of patients with multiple myeloma (MM) who were >75 years old. We identified 394 patients and for non-trial patients (n = 350), immunomodulatory drug (IMiD)+dex (32%) was the most commonly used regimen followed by alkylator with steroids or other therapy (21%), alkylator + proteasome inhibitor (PI)+steroid (18%), and IMiD + PI + dex (13%). Overall, achieving ≥ very good partial response was more in patients receiving a triplet compared to other therapies (46% vs. 21%, p < 0.0001). Also, the median overall survival (OS) was significantly longer in patients who were treated with a triplet (median OS: 50.2 vs. 32.8 months, p = 0.0006). In a multivariate for OS, receiving a triplet (HR: 0.65, p = 0.02), not having an R-ISS stage 3 (HR: 0.36, p = 0.0003), and bone marrow plasma cell percentage <60% (HR: 0.69, p = 0.03) were predictive. In conclusion, being able to receive triplet therapy was associated with better survival in our MM patients >75 years old.
AB - This is a retrospective study of patients with multiple myeloma (MM) who were >75 years old. We identified 394 patients and for non-trial patients (n = 350), immunomodulatory drug (IMiD)+dex (32%) was the most commonly used regimen followed by alkylator with steroids or other therapy (21%), alkylator + proteasome inhibitor (PI)+steroid (18%), and IMiD + PI + dex (13%). Overall, achieving ≥ very good partial response was more in patients receiving a triplet compared to other therapies (46% vs. 21%, p < 0.0001). Also, the median overall survival (OS) was significantly longer in patients who were treated with a triplet (median OS: 50.2 vs. 32.8 months, p = 0.0006). In a multivariate for OS, receiving a triplet (HR: 0.65, p = 0.02), not having an R-ISS stage 3 (HR: 0.36, p = 0.0003), and bone marrow plasma cell percentage <60% (HR: 0.69, p = 0.03) were predictive. In conclusion, being able to receive triplet therapy was associated with better survival in our MM patients >75 years old.
KW - Multiple myeloma
KW - elderly
KW - outcomes
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85110930483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110930483&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1950708
DO - 10.1080/10428194.2021.1950708
M3 - Article
C2 - 34263694
AN - SCOPUS:85110930483
SN - 1042-8194
VL - 62
SP - 3011
EP - 3018
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -